Messenger RNA vaccines against SARS-CoV-2

Cell. 2021 Mar 18;184(6):1401. doi: 10.1016/j.cell.2020.12.039. Epub 2021 Jan 13.

Abstract

The first two vaccines proven to be effective for inhibiting COVID-19 illness were both mRNA, achieving 95% efficacy (and safety) among 74,000 participants (half receiving placebo) after intramuscular delivery of two shots, 3-4 weeks apart. To view this Bench to Bedside, open or download the PDF.

MeSH terms

  • Antigen-Presenting Cells / immunology
  • B-Lymphocytes / immunology
  • COVID-19 / immunology*
  • COVID-19 / prevention & control*
  • COVID-19 / virology
  • COVID-19 Vaccines / immunology*
  • COVID-19 Vaccines / therapeutic use*
  • Drug Delivery Systems / methods
  • Humans
  • Liposomes
  • Nanoparticles
  • SARS-CoV-2 / immunology*
  • Spike Glycoprotein, Coronavirus / immunology
  • T-Lymphocytes / immunology
  • Treatment Outcome
  • Vaccines, Synthetic / immunology*
  • Vaccines, Synthetic / therapeutic use*

Substances

  • COVID-19 Vaccines
  • Lipid Nanoparticles
  • Liposomes
  • Spike Glycoprotein, Coronavirus
  • Vaccines, Synthetic
  • mRNA Vaccine
  • spike protein, SARS-CoV-2